CIBC Private Wealth Group
CLVS

CIBC Private Wealth Group’s Clovis Oncology, Inc. CLVS Stock Holding History

CIBC Private Wealth Group’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-500
Closed -$23K – 1829
2018
Q2 		$23K Buy
+500
New +$24.3K ﹤0.01% 1370

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PointState Capital
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

CIBC Private Wealth Group's CLVS Position: Q3 2018 in Review

CIBC Private Wealth Group sold out of Clovis Oncology, Inc. (CLVS) in Q3 2018, closing a stake of 500 shares — an estimated $23K sold.

CIBC Private Wealth Group first reported a position in CLVS in Q2 2018 and held it in 1 quarter. The position peaked at $23K in Q2 2018. 192 funds tracked by Wall St. Rank hold CLVS as of Q3 2018.

  • CIBC Private Wealth Group reported no remaining Clovis Oncology, Inc. position as of Q3 2018 after selling out during the quarter.
  • CIBC Private Wealth Group sold 500 Clovis Oncology, Inc. shares in Q3 2018, an estimated $23K.
  • CIBC Private Wealth Group first reported a position in Clovis Oncology, Inc. in Q2 2018 and held it in 1 quarter.
  • CIBC Private Wealth Group's Clovis Oncology, Inc. position peaked at $23K in Q2 2018.
  • 192 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2018.

Based on CIBC Private Wealth Group's 13F filing for Q3 2018, filed 14 Nov 2018.